Form 4: Travere Therapeutics Exec Reports Equity Transactions

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, reported the acquisition of restricted stock units and stock options, alongside a tax-related stock sale.

Summary

• Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, Inc. (TVTX), reported transactions involving the company's common stock and derivative securities.
• On January 31, 2026, Ms. Calvin acquired 15,180 shares of common stock through the settlement of restricted stock units at a price of $0 per share.
• Following this acquisition, her direct beneficial ownership of common stock increased to 53,413 shares.
• Also on January 31, 2026, Ms. Calvin was granted 20,160 employee stock options with an exercise price of $33.095 per share, expiring on January 31, 2036.
• One-fourth of these stock options will vest on January 31, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
• On February 3, 2026, Ms. Calvin sold 4,333 shares of common stock at a price of $32.12 per share.
• This sale was a non-discretionary 'sell to cover' transaction to satisfy tax withholding obligations related to the vested restricted stock units.
• After all reported transactions, Ms. Calvin directly beneficially owns 49,080 shares of common stock and 20,160 employee stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive, reflecting routine executive compensation and alignment through equity grants, with the sale being non-discretionary for tax purposes.

Positives

• The acquisition of restricted stock units and stock options indicates ongoing equity compensation for a key executive, aligning management interests with shareholder value.
• The grant of stock options provides a long-term incentive for the SVP, Chief Accounting Officer, to contribute to the company's future performance.

Negatives

• A sale of 4,333 shares occurred, though it was a non-discretionary 'sell to cover' transaction for tax withholding, not a discretionary sale by the executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings provide transparency into executive compensation and ownership, which can influence investor perception of management alignment. These routine equity grants and tax-related sales are common practices in the biotechnology and pharmaceutical industry for executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the interests of the SVP, Chief Accounting Officer, with shareholders, potentially fostering long-term value creation.
• Employees: This filing details compensation for a senior executive, which can be indicative of the company's overall compensation philosophy for key personnel.

Next Steps

• One-fourth of the granted stock options will vest and become exercisable on January 31, 2027.
• The remaining stock options will vest in 36 equal monthly installments after the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation and a non-discretionary tax-related sale by a key executive. It does not provide new information to alter the fundamental investment thesis for Travere Therapeutics, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant, Sell to Cover